The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance multiple TCR-TCEs over the next three years. The collaboration seeks to ...

Cancer cell death via necroptosis can be accompanied by the release of IL-1a, which can restrict anticancer immunity and promote tumor growth ...

Medigene announces KRAS G12V as first target for TCR-guided T cell engagers: Planegg, Germany Tuesday, December 10, 2024, 17:00 Hrs [IST] Medigene AG, an oncology platform company ...

The lab engineered molecules called trispecifics that connect cancer-killing T cells with not just one but two different brain cancer ... Glioblastoma: New Treatment Attacks Brain Tumors from ...

It has been suggested previously that fructose promotes the growth of some tumors directly—by serving as a fuel. Now, new ...

Illustration of a T cell attacking a cancer cell. (Science Photo Library/Canva) While immunotherapy has shown promise, it ...

Basal cell carcinoma (BCC) is the most common type of skin cancer worldwide, often producing shiny lesions on the skin that can be (but are not always) discolored. It develops in the basal cells, ...

Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

Dec. 5, 2024 — A groundbreaking phase one clinical trial explored a novel cell-based immunotherapy for breast cancer. The study focuses on a new treatment approach that aims to harness the body ...

A new 'cancer fingerprint' could improve early detection of the disease, according to scientists who say different types of ...